<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02175615</url>
  </required_header>
  <id_info>
    <org_study_id>CSA Cyclosporine PK Study</org_study_id>
    <nct_id>NCT02175615</nct_id>
  </id_info>
  <brief_title>Pharmacological Predictors of Successful Cyclosporine Acute GVHD Prophylaxis in Children Undergoing HSCT</brief_title>
  <official_title>PHARMACOLOGICAL PREDICTORS OF SUCCESSFUL CYCLOSPORINE ACUTE GRAFT VERSUS HOST DISEASE PROPHYLAXIS IN CHILDREN UNDERGOING HAEMATOPOIETIC STEM CELL TRANSPLANT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lee Dupuis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>C17 Council</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Hospital for Sick Children</source>
  <brief_summary>
    <textblock>
      The specific objectives of this study are:

      Primary:

      1)To determine the relationship between cyclosporine AUC achieved prior to engraftment and
      severe aGVHD (grade III and IV)

      Secondary:

        1. To determine the relationship between individual concentration-time points achieved
           prior to engraftment and severe aGVHD (grade III and IV)

        2. To validate the previously developed LSS to determine cyclosporine AUC after IV
           administration at steady state and

        3. To describe the relationship between cyclosporine AUC and individual concentration-time
           points achieved prior to engraftment and other HSCT outcomes (clinically significant
           aGVHD (grade II to IV), hypertension, engraftment failure, relapse
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Relationship between CSA area-under-the-curve (AUC) prior to ENGRAFTMENT and severe aGVHD</measure>
    <time_frame>Weekly for 7 weeks or until engraftment and for 100 days after HSCT</time_frame>
    <description>1)To determine the relationship between cyclosporine AUC achieved prior to engraftment and severe aGVHD (grade III and IV)</description>
  </primary_outcome>
  <enrollment type="Actual">105</enrollment>
  <condition>PHARMACOLOGICAL PREDICTORS OF SUCCESSFUL CYCLOSPORINE ACUTE GRAFT VERSUS HOST DISEASE PROPHYLAXIS IN CHILDREN UNDERGOING HAEMATOPOIETIC STEM CELL TRANSPLANT</condition>
  <eligibility>
    <study_pop>
      <textblock>
        ALLOGENEIC Hematopoietic stem cell transplant recipients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  less than 18 years of age

          -  undergoing allogeneic myeloablative HSCT at one of the participating centres and

          -  scheduled to receive cyclosporine for aGVHD prophylaxis

          -  minimum patient weight:

          -  6.4kg if &lt; 6 months old or 7.2kg if &gt; 6 months old

        All patients or guardians will provide informed consent or assent as appropriate. Initial
        contact will be made by a member of the patient's current care team. Consent will be
        obtained by a co-investigator or the CTSU personnel.

        Exclusion Criteria:

        -receipt of voriconazole or posaconazole within 14 days of the first cyclosporine dose or
        at any time until engraftment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Dupuis LL, Seto W, Teuffel O, Gibson P, Schultz KR, Doyle JD, Gassas A, Egeler RM, Sung L, Schechter T. Prediction of area under the cyclosporine concentration versus time curve in children undergoing hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2013 Mar;19(3):418-23. doi: 10.1016/j.bbmt.2012.10.031. Epub 2012 Nov 2.</citation>
    <PMID>23128321</PMID>
  </reference>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 24, 2014</study_first_submitted>
  <study_first_submitted_qc>June 25, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2014</study_first_posted>
  <last_update_submitted>January 19, 2016</last_update_submitted>
  <last_update_submitted_qc>January 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>The Hospital for Sick Children</investigator_affiliation>
    <investigator_full_name>Lee Dupuis</investigator_full_name>
    <investigator_title>Dr. Lee Dupuis</investigator_title>
  </responsible_party>
  <keyword>CYCLOSPORINE</keyword>
  <keyword>ACUTE GRAFT VERSUS HOST DISEASE</keyword>
  <keyword>PROPHYLAXIS</keyword>
  <keyword>CHILDREN</keyword>
  <keyword>HAEMATOPOIETIC STEM CELL TRANSPLANT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

